| 초록 |
Although the safety profiles of drug eluting stents (DES) do not seem to differ from those of bare metal stents (BMS) in the short-to-medium term, long-term failures have recently arisen from late thromboses related to delayed endothelialisation of the stent surface. Despite advances in polymer coating technology, there still seem to be no stent to effectively control both thrombosis and intimal hyperplasia. Therefore, our group is concerned about anti-thrombotic polymer coating rather than the coating for DES. In this presentation, metal-coating methods utilizing anti-thrombogenic biomolecules, such as heparin, and/or biocompatible polymersand their feasibility will be discussed. |
